Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

122.09 +0.89 (+0.73%)
Official Closing Price Updated: 4:10 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses
The company's second biggest product missed sales expectations. Shares look likely to undercut a buy zone. 
Via Investor's Business Daily
Topics Government Stocks
Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback
Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO succession plan amid strong drug sales. 
Via Benzinga
Earnings Scheduled For July 17, 2025
 
Via Benzinga
Earnings Outlook For Novartis
 
Via Benzinga
Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report
Via Stocktwits
How Do Investors Really Feel About Novartis?
 
Via Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
Divi’s Labs Shares Dip After Patent Loss: SEBI RA Recommends Buy On Dips
The stock slid to an intraday low of ₹6,545 on Monday following a gap-down open, as investors reacted to MSN’s legal win over Entresto. 
Via Stocktwits
Topics Intellectual Property
This Dividend ETF Is Near Its Highest Level Ever -- Is It Too Late to Invest in It?
Via The Motley Fool
Topics ETFs
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported. 
Via Benzinga
Novartis Gets Swiss Approval For First Malaria Drug For Babies
Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration. 
Via Benzinga
Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants
The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. 
Via Stocktwits
Topics Death Government
$1,000 in VEA Could Turn Into $57,000
Via The Motley Fool
Topics ETFs Economy
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...'
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery. 
Via Benzinga
Topics Artificial Intelligence
Better Dividend ETF to Buy for Passive Income: SCHD or GCOW
Via The Motley Fool
Topics ETFs Stocks
Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish
Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels. 
Via Stocktwits
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data. 
Via Benzinga
Is Pfizer Stock a Yield Trap?
Via The Motley Fool
Topics Intellectual Property
FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning
The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group. 
Via Stocktwits
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
Could This Be the Best High-Dividend ETF to Buy Right Now?
Via The Motley Fool
Topics ETFs Economy
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis. 
Via Stocktwits
Topics Intellectual Property
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations
Via Stocktwits
Topics Cannabis
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases. 
Via Benzinga
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Solid Value Pick in Pharmaceuticals
NOVARTIS AG (NYSE:NVS) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector. 
Via Chartmill
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.